Arnold LM, Williams DA, Hudson JI, Martin SA, Clauw DJ, Crofford LJ, Wang F, Emir B, Lai C, Zablocki R, Mease PJ. Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum. 2012 Mar 1;64(3):885-94.
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Presented at the 2008 Annual Meeting of the American College of Rheumatology; October 2008. San Francisco, CA. [abstract] Arthritis Rheum. 2008 Sep; 58(9 Suppl):S782.
Keeenan AM, McKenna SP, Doward LC, Conaghan PC, Emery P, Tennant A. OAQoL: the development and validation of a needs-based quality of life instrument for osteoarthritis. Arthritis Rheum. 2008 Jun 1;59(6):841-8.
Manga N, Duffy JC, Rowe PH, Cronin MTD. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ Res. 2005 Feb;16(1-2):43-61.
Cronin MT, Dearden JC, Duffy JC, Edwards R, Manga N, Worth AP, Worgan AD. The importance of hydrophobicity and electrophilicity descriptors in mechanistically-based QSARs for toxicological endpoints. SAR QSAR Environ Res. 2002 Mar;13(1):167-76.